News/ News/ Oncology New era of genomic medicine begins as UK approves Lilly’s Retsevmo Richard Staines Eli Lilly, Merck & Co, MHRA, Oncology, RET inhibitors, thyroid cancer 0 Comment The UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung Share X New era of genomic medicine begins as UK approves Lilly’s Retsevmo https://pharmaphorum.com/news/uk-authorises-lillys-ret-targeted-retsevmo/